Market Overview:
Lyme disease is the most common vector-borne disease in the United States. Lyme disease is caused by the bacterium Borrelia burgdorferi and rarely, Borrelia mayonii. It is transmitted to humans through the bite of infected blacklegged ticks. Typical symptoms include fever, headache, fatigue, and a characteristic skin rash and other. Lyme disease can be treated successfully with a few weeks of antibiotics. Steps to prevent Lyme disease include using insect repellent, removing ticks promptly, applying pesticides, and reducing tick habitat.
Attributes | Details |
---|
Study Period | 2017-2027 |
Base Year | 2021 |
Forecast Period | 2022-2027 |
Historical Period | 2017-2021 |
Unit | Value (USD Million) |
Key Companies Profiled | GlaxoSmithKline plc (United Kingdom), Pfizer, Inc. (United States), Novartis AG (Switzerland), Almirall, LLC (United States), Mayne Pharma (United States), Galderma Laboratories, L.P. (United States), Lupin Pharmaceuticals, Inc. (United States), Chartwell Pharmaceuticals (United States), Sun Pharmaceutical Industries Ltd (India) and Amneal Pharmaceuticals LLC. (United States) |
Customization Scope | Avail customization with purchase of this report. Add or modify country, region or narrow down segments in the final scope subject to feasibility |
AMA Research follows a focused and realistic research framework that provides the ability to study the crucial market dynamics of major and emerging geographies across the world. Moreover, an in-depth assessment is mostly conducted by our analysts on geographical regions to provide clients and businesses the opportunity to dominate in niche markets and expand in emerging markets across the globe. This market research study also showcases the spontaneously changing Players landscape impacting the growth of the market. Furthermore, our market researchers extensively analyze the products and services offered by multiple players competing to increase their market share and presence.
Key Players of Lyme Disease Treatment Market Study:
GlaxoSmithKline plc (United Kingdom), Pfizer, Inc. (United States), Novartis AG (Switzerland), Almirall, LLC (United States), Mayne Pharma (United States), Galderma Laboratories, L.P. (United States), Lupin Pharmaceuticals, Inc. (United States), Chartwell Pharmaceuticals (United States), Sun Pharmaceutical Industries Ltd (India) and Amneal Pharmaceuticals LLC. (United States)
Lyme Disease Treatment Market Segment Analysis
Scope | Sub-Segments |
---|
Application / End User | Humans and Animals |
Type | Doxycycline, Amoxicillin, Cefuroxime axetil, Ceftriaxone and Others |
Disease | Early Lyme disease (absence of erythema migrans),Lyme carditis,Lyme arthritis,Neurologic Lyme disease,Borrelial lymphocytosis,Post-treatment Lyme Disease Syndrome |
Symptoms | Fever,Headaches,Chills,Joint aches,Swollen lymph nodes |
Influencing Trend:
High Investments in Healthcare R&D
Market Growth Drivers:
Rising prevalence of lyme disease and Rising geriatric population
Challenges:
Fierce competitive pressure and High cost of treatment
Restraints:
Lack of awareness about the disease and Technical complexities related to diagnostic test
Opportunities:
High governmental healthcare expenditure and Surging insurance penetration
.
Research Methodology:
The top-down and bottom-up approaches are used to estimate and validate the size of the Global Lyme Disease Treatment market.
In order to reach an exhaustive list of functional and relevant players, various industry classification standards are closely followed such as NAICS, ICB, SIC to penetrate deep into important geographies by players, and a thorough validation test is conducted to reach the most relevant players for survey in Lyme Disease Treatment market.
Identification of total players or companies operating in the global market which is further concentrated to fewer or most impacting players which are considered under the reports scope. In order to make a priority list sorting is done based on revenue generated based on the latest reporting with the help of paid databases such as Factiva, Bloomberg, etc.
Finally the questionnaire is set and specifically designed to address all the necessities for primary data collection after getting prior appointment by targeting key target audience that includes Lyme Disease Treatment Provider, New Entrants and Investors, Venture Capitalists, Government Bodies, Corporate Entities, Government and Private Research Organizations and Others.
This helps us to gather the data for the players revenue, operating cycle and expense, profit along with product or service growth, etc.
Almost 70-80% of data is collected through primary medium and further validation is done through various secondary sources that include Regulators, World Bank, Association, Company Website, SEC filings, OTC BB, Annual reports, press releases etc.